Eton Pharmaceuticals Inc. (ETON) Insider Trading

Last 12 months

Insiders sold $19.6M and bought nothing on the open market.

None of the selling was scheduled in advance under a 10b5-1 plan. President & CEO Sean Brynjelsen sold $6.09M on Aug 20, 9.4% of their stake, outside a plan. The last open-market buy by an executive or director was in Sep 2022.

Net open-market

−$19.6M

0 buys · 7 sales

Under a 10b5-1 plan

of the value sold

Insiders who bought / sold

0 / 4

executives and directors

Last open-market buy

Sep 2022

Sep 22, 2022

Get an email when ETON's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

Date	Insider	Trade	Shares	Price	Value	Of their stake	Filing
Oct 6	David Krempa Chief Business Officer	SoldNo plan	4,166	$55.07	$229k	8.8%	Form 4
Aug 28	Paul V Maier Director	SoldNo plan 3 parts	50,000	$59.07 average	$2.95M	41%	Form 4
Aug 24	David Krempa Chief Business Officer	SoldNo plan	25,000	$65.07	$1.63M	40%	Form 4
Aug 19 – 20	Sean Brynjelsen President & CEO	SoldNo plan 4 parts	100,000	$60.88 average	$6.09M	9.4%	Form 4
Jul 14	Opaleye Management Inc. Large holder	SoldNo plan 2 parts	28,315	$37.54 average	$1.06M	1.0%	Form 4
Jul 2 – 7	Opaleye Management Inc. Large holder	SoldNo plan 5 parts	126,685	$37.64 average	$4.77M	4.4%	Form 4
Jun 17	Jennifer McKie Adams Director	SoldNo plan	50,000	$32.48	$1.62M	100%	Form 4
May 28	Sean Brynjelsen President & CEO	SoldNo plan 2 parts	120,000	$31.88 average	$3.83M	13%	Form 4
May 22 – 27	David Krempa Chief Business Officer	SoldNo plan 5 parts	100,000	$32.30 average	$3.23M	80%	Form 4
Aug 19, 2025 – Aug 20, 2025	James R. Gruber Chief Financial Officer	SoldNo plan 2 parts	41,713	$16.15 average	$674k	17%	Form 4
Jun 12, 2025 – Jun 16, 2025	David Krempa Chief Business Officer	SoldNo plan 3 parts	34,000	$14.83 average	$504k	5.3%	Form 4
Jun 10, 2025	Opaleye Management Inc. Large holder	Bought 2 parts	7,930	$15.82 average	$125k	0.3%	Form 4
Jun 3, 2025 – Jun 5, 2025	Sean Brynjelsen President & CEO	SoldNo plan 5 parts	210,000	$17.11 average	$3.59M	6.8%	Form 4

Oct 6No plan
David Krempa
Chief Business Officer · sold 4,166 at $55.07
$229k
8.8% of stake
Aug 28No plan
Paul V Maier
Director · sold 50,000 at avg $59.07
$2.95M
41% of stake
Aug 24No plan
David Krempa
Chief Business Officer · sold 25,000 at $65.07
$1.63M
40% of stake
Aug 19 – 20No plan
Sean Brynjelsen
President & CEO · sold 100,000 at avg $60.88
$6.09M
9.4% of stake
Jul 14No plan
Opaleye Management Inc.
Large holder · sold 28,315 at avg $37.54
$1.06M
1.0% of stake
Jul 2 – 7No plan
Opaleye Management Inc.
Large holder · sold 126,685 at avg $37.64
$4.77M
4.4% of stake
Jun 17No plan
Jennifer McKie Adams
Director · sold 50,000 at $32.48
$1.62M
100% of stake
May 28No plan
Sean Brynjelsen
President & CEO · sold 120,000 at avg $31.88
$3.83M
13% of stake
May 22 – 27No plan
David Krempa
Chief Business Officer · sold 100,000 at avg $32.30
$3.23M
80% of stake
Aug 19, 2025 – Aug 20, 2025No plan
James R. Gruber
Chief Financial Officer · sold 41,713 at avg $16.15
$674k
17% of stake
Jun 12, 2025 – Jun 16, 2025No plan
David Krempa
Chief Business Officer · sold 34,000 at avg $14.83
$504k
5.3% of stake
Jun 10, 2025
Opaleye Management Inc.
Large holder · bought 7,930 at avg $15.82
$125k
0.3% of stake
Jun 3, 2025 – Jun 5, 2025No plan
Sean Brynjelsen
President & CEO · sold 210,000 at avg $17.11
$3.59M
6.8% of stake

How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch ETON, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Related stocks: Pharmaceutical Preparations

XNCRXencor Inc.

TBPHTheravance Biopharma Inc.

ASRTAssertio Holdings Inc.

SEPNSepterna, Inc.

AGIOAgios Pharmaceuticals Inc.

GYREGyre Therapeutics Inc.

SPRYArs Pharmaceuticals Inc

RCUSArcus Biosciences Inc.

Spot a number that looks wrong? Check it in ETON's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing ETON

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.